A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Study Summary

This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.

Conditions

Intrahepatic Cholangiocarcinoma (Icc)Cholangiocarcinoma Other Solid Tumors, Adult FGFR2 Gene Fusion/Rearrangement FGFR2 Gene Amplification FGFR2 Gene Short Variants FGFR3 Gene Fusion/Rearrangement FGFR3 Gene Amplification FGFR3 Gene Short Variants FGFR2 Genetic Alterations FGFR3 Genetic Alterations Advanced Solid Tumors

Interventions / Drugs

CGT4859

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment110 participants

Primary Completion—

Lead SponsorCogent Biosciences, Inc.

Data Retrieved2026-04-11 04:10:18.672983+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.